Experts from NYU Langone's Department of Medicine, Division of Rheumatology presented new research and participated in expert panel discussions at the American College of Rheumatology 2013 Annual Meeting in San Diego, CA, October 26-30.
"We are thrilled for the opportunity to present important findings that may lead to new therapies for several autoimmune and rheumatic conditions," said Jill P. Buyon, MD, professor and director, Department of Medicine, Division of Rheumatology at NYU Langone Medical Center. "This meeting provides an opportunity to contribute to the growing body of knowledge regarding inflammatory disease while collaborating with other leaders in the field to ensure information sharing among clinicians and ultimately help enhance patient care."
Significant research presentations from NYU Langone rheumatologists will include:
First Stage of a Simon's Two-Stage Optimal Approach Supports Placental Transfer of Hydroxychloroquine and a Reduced Recurrence Rate of the Cardiac Manifestations of Neonatal Lupus
Presenter: Peter M. Izmirly, MD; Co-Authors: Nathalie Costedoat-Chalumeau, MD, PhD; Amit Saxena, MD; Amanda Zink; Zoey A. Smith; Deborah Freidman, MD; Jill P. Buyon, MD
Wednesday, October 30, 2013 at 9:00A PDT
Women with anti-Ro antibodies, an antibody present in both Systemic Lupus Erythematosus (SLE) and Sjogren's Syndrome, are faced with the possibility of having a child with a permanent and sometimes fatal heart condition. Women who have had one child with this heart problem are at high risk for having a second affected child. To date, no therapies have proven effective in prevention. Data generated at NYU Langone show promise for a drug called hydroxychloroquine (HCQ), an anti-inflammatory agent, to prevent recurrent heart disease. If these findings are further substantiated, HCQ may gain widespread acceptance for use in these at risk pregnancies.
Accounting For Parental Load and Identification of Multiple Risk Variants for Anti-Ro Congenital Heart Block Through High-Density Genotyping Of Immune-Related Loci
Presenter: Robert Clancy, PhD; Co-authors: Jill P. Buyon, MD; Nathalie Costedoat-Chalumeau, MD, PhD; Antonio Brucato, MD; Kateri Levesque, FRCP(C), FRCPC, MD; Vronique Ramoni, MD; Miranda C. Marion, MA; Mary Comeau, MA; Satria Sajuthi, MS; Paula S. Ramos, PhD; Robert P. Kimberly, MD; Timothy D. Howard, PhD; Carl D. Langefeld, PhD
Wednesday, October 30, 2013 at 11:15A PDT
Fetuses of mothers who are otherwise healthy, or suffer from a rheumatic disease but have autoantibodies to SSA/Ro, are at risk for having permanent heart damage which may be fatal or require lifelong pacing. Prior genetic studies, as well as bench research, highlight injury secondary to an excessive immune response. The goal of this study was to determine the role of the genetic composition of the fetus while accounting for the maternal autoimmune disease load. An immunochip platform and association study were performed using subjects from an international cohort of US, France and Italy. The results yielded a panel of confirmed and newly identified risk genes. These genetic building blocks represent important milestones towards clarifying the mechanism by which these autoantibodies cause cardiac scarring a critical component to treatment/prevention strategies.
For more information on abstracts, presentations and seminars, visit American College of Rheumatology Sessions 2013.
|Contact: Craig Andrews|
NYU Langone Medical Center / New York University School of Medicine